BioCentury
ARTICLE | Company News

Cambridge Antibody, Human Genome Sciences, Dow Chemical deal

November 6, 2000 8:00 AM UTC

HGSI exercised its option under a 1999 agreement to acquire exclusive global development rights to antibodies generated by CAT against HGSI’s BLyS B-Lymphocyte Stimulator target (see BioCentury, Aug. 16, 1999). HGSI said it plans to start clinical development of the antibody for autoimmune and neoplastic disorders in 2001. CAT will receive license fees, milestones and royalties. ...